Multi-Center PAMPA Study

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.

NCT Number	NCT05004727
Lead Sponsor	NYU Langone Health Collaborators: Janssen Scientific Affairs, LLC
Conditions	Psoriasis
Enrollment	176 participants
Start Date	2022-02-16
Primary Completion	2026-12-31 (estimated)
Study Completion	2028-11-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-30